Google, Meta, and Isomorphic Labs Join Forces on Virtual Cell

Google DeepMind, Meta, and AI drug discovery startup Isomorphic Labs are jointly investing $300 million into an initiative to create a “virtual cell” that researchers can use to study and combat disease. The project is led by Biohub, a nonprofit biomedical research organization founded by Mark Zuckerberg and his wife, Priscilla Chan. The investment is part of a larger $1.8 billion “Virtual Biology” initiative designed to build AI datasets that could allow researchers to “ask, predict, and answer biological questions digitally.”

The announcement marks one of the most significant collaborations to date between leading artificial intelligence companies and biomedical research. By pooling resources, the partners hope to create a computational model of a cell that is accurate enough to simulate how cells behave, respond to treatments, and malfunction in disease. If successful, such a model could fundamentally change how scientists approach drug discovery, diagnostics, and personalized medicine.

What Is a Virtual Cell?

A virtual cell is not a literal digital replica of every molecule in a living cell. Instead, it is a high-accuracy predictive model built from vast amounts of biological data and trained using machine learning. Researchers would use it to run simulations—digital experiments—that predict how a cell might react to genetic mutations, drugs, environmental changes, or infections. The goal is to give scientists a way to test hypotheses quickly and cheaply before running physical experiments in a lab.

Creating such a model is extraordinarily difficult. Cells are complex systems with thousands of genes, proteins, metabolites, and signaling pathways interacting in ways that are still not fully understood. Even a single cell type can behave differently depending on its environment, its stage in the cell cycle, and the presence of neighboring cells. A predictive model must capture this complexity while remaining computationally tractable.

Biohub’s approach relies on generating large, standardized datasets that AI systems can learn from. These datasets must cover many cell types, conditions, and perturbations. The Virtual Biology initiative aims to coordinate data generation at a national and international scale, bringing together academic labs, government agencies, and private companies.

Biohub’s Mission and History

Biohub was founded in 2016 with a mission to prevent and cure disease by advancing biomedical research. It supports scientists working on infectious diseases, immunology, cell biology, and related fields. The organization has backed projects such as the Human Cell Atlas, which aims to map every cell type in the human body, and the Rapid Response program for emerging pathogens.

The virtual cell project fits Biohub’s long-term vision of creating a “high-accuracy predictive model of the cell.” According to Biohub, such a model would allow researchers to carry out simulations that reveal how biological systems work and how they fail. The organization argues that an accurate predictive model of biology could dramatically accelerate scientific discovery by enabling scientists to perform experiments digitally.

Alex Rives, Biohub’s head of science, described the virtual cell as one of the most important challenges for the next era of science. “An accurate predictive model of biology could dramatically accelerate scientific discovery by enabling scientists to perform experiments digitally,” Rives said in a press release. “The creation of a virtual cell is one of the most important challenges for the next era of science. It will require coordinated data generation efforts at a national and international scale, which is why these partners are coming together.”

The $1.8 Billion Virtual Biology Initiative

The $300 million investment from Google DeepMind, Meta, and Isomorphic Labs is part of a broader $1.8 billion “Virtual Biology” initiative. That initiative is intended to build AI datasets and models that can answer biological questions digitally. The scale of the funding reflects both the ambition of the project and the recognition that no single organization can solve the problem alone.

The U.S. Department of Energy will invest more than $500 million over the next five years in the initiative. The National Institutes of Health will contribute datasets, repositories, and knowledge bases stemming from previous federal investment totaling more than $500 million. These contributions are expected to provide a foundation of biological data that AI models can use for training and validation.

The involvement of federal agencies highlights the growing interest of governments in AI-driven biology. Governments see virtual cell models as a way to speed up biomedical research, reduce the cost of drug development, and improve preparedness for future health crises. The datasets held by agencies like the NIH represent decades of public investment in biomedical research, and making them available for AI training could multiply their value.

Why Google, Meta, and Isomorphic Labs Are Investing

Google DeepMind has already made significant contributions to computational biology. Its AlphaFold system predicted the three-dimensional structures of millions of proteins, a breakthrough that has been widely used by researchers around the world. DeepMind has also worked on models for protein design, genomics, and molecular simulation. A virtual cell would be a natural next step, extending AI from static structures to dynamic cellular processes.

Meta has invested heavily in AI research, including models for protein folding and biological foundation models. The company has released open-source tools and datasets for computational biology, and it has collaborated with academic groups on projects such as the ESM protein language models. Meta’s involvement in the virtual cell initiative could bring expertise in large-scale machine learning, infrastructure, and open science.

Isomorphic Labs is an AI drug discovery company spun out of Google DeepMind. It aims to use AI to design new medicines more efficiently. A virtual cell would be directly relevant to its work because drug discovery depends on predicting how potential treatments affect cells and tissues. If Isomorphic Labs can use a virtual cell to test drug candidates digitally, it could reduce the time and cost of preclinical research.

The collaboration also reflects a broader trend: AI companies are moving deeper into the life sciences. The tools and models developed for language, vision, and games are increasingly being applied to biological data. Biology is seen as one of the most promising domains for AI because it generates massive, complex datasets and because breakthroughs can have enormous societal impact.

How a Virtual Cell Could Change Research

If a virtual cell works as intended, it could change the way researchers approach basic biology and medicine. Scientists could ask questions such as: What happens if this gene is turned off? How will this cancer cell respond to a new drug? Which combination of treatments is likely to be most effective for a patient with a specific mutation? They could get answers in silico—on a computer—before committing time and resources to laboratory experiments.

Digital experiments offer several advantages. They are faster, cheaper, and can be run at a scale that is impossible in a physical lab. They can also be used to explore conditions that are difficult or unethical to test in humans or animals. For example, a virtual cell could simulate the effects of a rare genetic disease or a toxic chemical exposure without harming a living organism.

However, virtual experiments are only useful if they accurately reflect reality. A model that makes incorrect predictions could waste resources or lead researchers astray. That is why the initiative places heavy emphasis on data quality, validation, and reproducibility. The datasets used to train the model must be carefully curated, and the model’s predictions must be tested against real-world experiments.

Challenges in Building a Virtual Cell

Building a virtual cell is a massive scientific and engineering challenge. One obstacle is data integration. Biological data comes in many forms: DNA sequences, RNA expression levels, protein structures, metabolite concentrations, microscopy images, and clinical records. These data are generated using different technologies, stored in different formats, and often lack standard metadata. Integrating them into a single model requires significant effort in data harmonization and ontology development.

Another challenge is scale. A human cell contains billions of molecules. Simulating every molecular interaction from first principles is computationally impossible for the foreseeable future. Instead, researchers must use AI models that learn patterns from data and make predictions at higher levels of abstraction. These models must balance accuracy with efficiency.

A third challenge is causality. AI models are good at finding correlations, but they do not automatically understand cause and effect. A virtual cell must be able to predict what happens when a system is perturbed, not just describe what is observed. That requires models that can reason about interventions and counterfactuals.

Finally, there are ethical, legal, and social considerations. A virtual cell could be used to develop new medicines, but it could also be used to design dangerous biological agents. Ensuring that the technology is used responsibly will require governance, oversight, and international cooperation.

Key Facts

• Google DeepMind, Meta, and Isomorphic Labs are jointly investing $300 million in a virtual cell initiative.
• The project is led by Biohub, a nonprofit founded by Mark Zuckerberg and Priscilla Chan in 2016.
• The investment is part of a $1.8 billion Virtual Biology initiative to build AI datasets for digital biological experiments.
• The U.S. Department of Energy will invest more than $500 million over five years.
• The National Institutes of Health will contribute datasets, repositories, and knowledge bases from prior federal investment totaling over $500 million.
• Biohub aims to create a high-accuracy predictive model of the cell that researchers can use for simulations.
• Alex Rives, Biohub’s head of science, says the virtual cell is one of the most important challenges for the next era of science.
• The initiative emphasizes coordinated data generation at national and international scales.

Industry and Scientific Context

The virtual cell initiative arrives amid a wave of investment in AI for biology. Pharmaceutical companies are increasingly using machine learning to identify drug targets, design molecules, and predict toxicity. Startups are building AI platforms for protein engineering, cell therapy, and precision medicine. Universities are creating new centers that combine computer science, biology, and engineering.

At the same time, biological data is growing exponentially. Single-cell sequencing, spatial transcriptomics, cryo-electron microscopy, and high-content imaging are producing unprecedented amounts of information about how cells work. The challenge is no longer generating data but making sense of it. AI models that can integrate and interpret these data could unlock new insights into health and disease.

Foundations such as Biohub are playing a catalytic role by funding risky, long-term projects that may not attract immediate commercial investment. By bringing together government, industry, and academia, the virtual cell initiative aims to create a shared infrastructure that benefits the entire research community. If successful, it could become a foundational resource for biology in the same way that reference genomes and protein structure databases have become essential tools.

What Comes Next

The partners have not announced a detailed timeline for when a fully functional virtual cell might be available. Building such a model will likely take years, if not decades, and will require iterative improvements. Early versions may focus on specific cell types, such as cancer cells, immune cells, or stem cells. Over time, the models could expand to cover more cell types, tissues, and eventually whole organisms.

In the near term, the initiative is expected to focus on data generation, standardization, and model development. The Department of Energy’s funding will support computational infrastructure and data generation. The NIH’s contributions will provide access to existing datasets and biological repositories. Google DeepMind, Meta, and Isomorphic Labs will contribute AI expertise, engineering talent, and computational resources.

For researchers, the project promises new tools for asking biological questions. For patients, it offers the hope of faster drug development and more personalized treatments. For the companies involved, it represents a strategic bet that AI can solve some of the hardest problems in biology. Whether the virtual cell becomes a reality remains to be seen, but the investment signals that the ambition is being taken seriously at the highest levels of technology and government.

The effort also underscores how competition and collaboration coexist in AI. Google, Meta, and Isomorphic Labs are rivals in some areas, but they are partners in this initiative because the challenge is too large for any one player. By sharing data, models, and expertise, they hope to accelerate progress for everyone. The virtual cell, if it works, would be a shared scientific resource—one that could change how humanity understands and treats disease.

As Alex Rives put it, the creation of a virtual cell will require coordinated data generation efforts at a national and international scale. The partners are now coming together to meet that challenge. Their success will depend on sustained funding, scientific creativity, and a commitment to open, rigorous, and responsible research.

Source: The Verge News